COVID-19 preclinical drug development database

Novel covalent inhibitors of SARS-CoV-2 main protease

Newcastle University

Added 01/06/2020 | Updated 01/06/2020

Project Details

Type of project

  • Tier 3: discovering and categorising new molecules

Therapeutic target

  • Preventing virus replication in early disease
  • Direct acting antiviral

Type of supporting technology

Phase of project

  • Lead optimisation and activity validation

Modality (if can be disclosed)*

  • Small molecule

Molecular/cellular target (if known or can be disclosed)*

  • SARS-CoV-2 main protease

Partner institutions/organisations

  • Diamond Light Source

Key contact

Name: Mike Waring

Email Address: mike.waring@ncl.ac.uk

Phone Number: +441912088591

Key Collaborators:
Mike Waring, Martin Noble, Steve Wedge, Chris Duncan

Anticipated timeframe of future outputs

This research project is looking for the following:

Currently seeking follow-on funding

Further Details

Abstract or additional information (if available)*

Published outputs (if available)*

https://www.biorxiv.org/content/10.1101/2020.05.27.118117v1

Relevant weblinks

Similar Projects

Project Name
Lead institution